Microsoft shares jump after fourth-quarter earnings beat on AI-fueled cloud growth
FORT LAUDERDALE - SS Innovations International, Inc. (NASDAQ:SSII), a $1.63 billion market cap surgical robotics company that has seen its stock surge nearly 98% over the past year, announced that its Chairman and CEO Dr. Sudhir Srivastava successfully performed the world’s first intercontinental robotic cardiac telesurgery on July 19, 2025.
The procedure, a robotic atrial septal defect closure, was conducted remotely from IRCAD headquarters in Strasbourg, France, while the patient was located at Sri Aurobindo Institute of Medical Sciences (SAIMS) in Indore, India—a distance exceeding 4,000 miles.
The surgery utilized the company’s SSi Mantra 3 surgical robotic system and was performed during the Society of Robotic Surgery Annual Meeting. According to the company, the procedure was completed with "imperceptible latency" and without technical issues.
Patient-side support in India was coordinated by a team of specialists including Dr. Lalit Malik from Manipal Hospital, Dr. Ram Krishna Shukla and Dr. Bipin Arya from SAIMS. Dr. Husam H. Balkhy, President of the International Society for Minimally Invasive Cardiothoracic Surgery, moderated the live telesurgery.
SS Innovations reports that 35 telesurgeries, including 10 cardiac procedures, have been performed using the SSi Mantra system to date. The company, which has achieved impressive revenue growth of 177% in the last twelve months to $22.13 million, states that over 5,000 multi-specialty surgeries have been completed with the system without device-related adverse events.
The SSi Mantra system features 3 to 5 modular robotic arms, a 3D 4K monitor, and can utilize over 40 different types of robotic endo-surgical instruments.
SS Innovations is the only surgical robotic company to have received regulatory approval from India’s Central Drugs Standard Control Organization for both teleproctoring and telesurgery, according to the press release statement. Want deeper insights into SSII’s financial health and growth potential? InvestingPro offers exclusive analysis with 10 additional ProTips and comprehensive financial metrics.
In other recent news, SS Innovations International, Inc. has announced that it has installed more than 100 SSi Mantra surgical robotic systems globally, marking significant growth in its deployment. The company also reported that over 5,000 surgical procedures have been successfully performed using the SSi Mantra system, including 240 cardiac surgeries and 32 telesurgeries. Additionally, SS Innovations completed what it claims is the world’s first robotic telesurgery for weight loss, connecting surgeons over a distance of 560 miles in India. In a significant development for the Americas, the first robotic cardiac surgery was performed using the SSi Mantra 3 system in Ecuador.
The company is also planning to submit a De Novo Classification Request to the U.S. Food and Drug Administration for its SSi Mantra 3 system in July 2025, which could allow marketing in the United States. SS Innovations has already installed 80 of these systems globally, facilitating over 3,800 surgeries. In leadership news, the company appointed Dr. Vishwajyoti P. Srivastava as the new CEO for the Asia Pacific region, effective May 21, 2025, as part of its strategy to strengthen its leadership team.
These developments come as SS Innovations continues to expand its presence in the surgical robotics market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.